Endocrinology Test
|
|
| 1. 21 hydroxylase deficiency: |
|
|
| 2. The confirmatory marker of Graves’ disease is: |
|
|
| 3. The most frequent secretory pituitary adenoma is represented by: |
|
|
| 4. The following is false regarding nonfunctional pituitary adenoma: |
|
|
| 5. First line therapy in prolactinomas is represented by: |
|
|
| 6. The mortality rate in differentiated thyroid cancer at 5 years are: |
|
|
| 7. Bone quality is dependent of: |
|
|
| 8. The etiology of pituitary insufficiency includes: |
|
|
| 9. Inhibitory neurohormones from the hypothalamus are represented by: |
|
|
| 10. Parathyroid localization evaluation: |
|
|
| 11. Addison's disease: |
|
|
| 12. The clinical picture of hypopituitarism includes: |
|
|
| 13. Type II of primary osteoporosis: |
|
|
| 14. The clinical picture of congenital myxedema includes: |
|
|
| 15. The following are true regarding fine needle aspiration for thyroid nodules: |
|
|
| 16. In females FSH : |
|
|
| 17. In central diabetes insipidus : |
|
|
| 18. In primary hypothyroidism laboratory investigations can reveal: |
|
|
| 19. In primary hyperaldosteronism: |
|
|
| 20. The following are true regarding the use of computer tomography in pituitary tumor evaluation: |
|
|
| 21. The peak bone mass is dependent on: |
|
|
| 22. The following are true regarding nodular thyroid disease: |
|
|
| 23. Under the possible effects of growth hormone we can observe: |
|
|
| 24. The control mechanisms of arginine vasopressin release include: |
|
|
| 25. Bone formation agents used as osteoporosis treatment are represented by: |
|